Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1915481 | Journal of the Neurological Sciences | 2008 | 6 Pages |
Abstract
We have recently observed that the corticotropin releasing factor related peptide urocortin (UCN) reverses key features of nigrostriatal neurodegeneration following intracerebral injection of either 6-hydroxydopamine (6-OHDA) or lipopolysaccharide (LPS). To determine the potential therapeutic utility of UCN here we have studied whether these effects are sustained for several weeks following peptide injection. In addition we have studied whether UCN still shows efficacy in rats with more pronounced nigrostriatal lesions. Rats were lesioned using 6-OHDA or LPS and injected with UCN either 7 or 14Â days later. At different time points animals were tested for rotational behaviour (apomorphine, 0.5Â mg/kg) and subsequently implanted with bilateral dialysis probes into the striata. The following day rats were dialysed to estimate extracellular striatal dopamine (DA) and then sacrificed for estimation of striatal tissue DA and subsequent immunohistochemistry of TH+ cells in the substantia nigra (SN). Toxin treated rats given UCN 7Â days later showed clear evidence of reduced nigrostriatal damage both 28 and 84Â days following UCN compared with saline injection. In rats given UCN 14Â days after toxin injection, by which time deficits were maximal, a restoration of nigrostriatal damage was observed. This suggests that UCN is able to elicit a sustained restoration of functional nigrostriatal integrity and has the ability to produce a recovery in severely lesioned rats. These findings suggest that stimulation of CRF (probably CRF1) receptors could have therapeutic utility in PD.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Amjad Abuirmeileh, Alexander Harkavyi, Ann Kingsbury, Rebecca Lever, Peter S. Whitton,